Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib

Joensuu, Heikki; Wardelmann, Eva; Sihto, Harri; Eriksson, Mikael; Sundby Hall, Kirsten; Reichardt, Annette; T. Hartmann, Jörg; Pink, Daniel; Cameron, Silke; Hohenberger, Peter; Al‐Batran, Salah‐Eddin; Schlemmer, M.; Bauer, Sebastian; Nilsson, Bengt; Kallio, Raija; Junnila, Jouni; Vehtari, Aki; Reichardt, Peter

doi:10.1001/jamaoncol.2016.5751

Public

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib

Published in JAMA Oncology • Mar 24, 2017

Authors:

Heikki Joensuu

Eva Wardelmann

Harri Sihto

Abstract

IMPORTANCE: Little is known about whether the duration of adjuvant imatinib influences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor α (PDGFRA) mutations. OBJECTIVE: To investigate the effect of KIT and PDGFRA mutations o...

Subject

PDGFRA

Medicine

Imatinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!